About: The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis
Creator	Jiang, S Fadia, M Gibson, K Konia, M Puri, P Walters, G
source	Medline; PMC
abstract	BACKGROUND: C3 glomerulonephritis is a recently described entity with heterogeneous histopathological features. This study was conducted to assess the effect of reclassification of C3 glomerulopathies on renal outcomes, mortality, and response to therapy. METHODS: We undertook a retrospective analysis of 857 renal biopsies collected at The Canberra Hospital. Samples with predominant C3 staining were reviewed by a renal histopathologist. Of 31 biopsies with predominant C3 staining, 10 fulfilled histological criteria for C3 glomerulonephritis, while the remaining 21 cases were used as C3 Controls. RESULTS: Aside from a higher incidence of C3 glomerulonephritis in Torres Strait islanders (40% vs 5% C3 Controls, p = 0.04), presentation demographics were similar between the two groups. Median creatinine at diagnosis was higher in patients with C3 glomerulonephritis (253 umol/L IQR 103–333 vs 127 umol/L C3 Controls, IQR 105–182, p = 0.01). Prior to reclassification, a majority of C3 glomerulonephritis cases were diagnosed as membranoproliferative glomerulonephritis (60% vs 5% (C3 Controls) p < 0.01). Electron microscopy demonstrated all C3 glomerulonephritis patients had C3 deposition (100% vs 38% p = 0.02), these deposits were amorphous in nature (50% vs 5% respectively p = 0.007). C3 glomerulonephritis patients had shorter median follow-up (405 days IQR 203–1197 vs 1822 days respectively, IQR 1243–3948, p = 0.02). Mortality was higher in C3 glomerulonephritis patients (30% vs 14% in C3 Controls (log rank p = 0.02)). CONCLUSION: We have devised a diagnostic and treatment algorithm based on the results of literature review and our current study. Further prospective assessment is required to review diagnostic and treatment outcomes for this disease in Australian centres.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1186/s12882-020-01923-5
bibo:pmid	32652953
has license	cc-by
sha1sum (hex)	f907ce26c8ff43f99a87f773eda4850d278299ab
schema:url	https://doi.org/10.1186/s12882-020-01923-5
resource representing a document's title	The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis
has PubMed Central identifier	PMC7351649
has PubMed identifier	32652953
schema:publication	BMC Nephrol
resource representing a document's body	covid:f907ce26c8ff43f99a87f773eda4850d278299ab#body_text
is schema:about of	named entity 'glomerulonephritis' named entity 'impact' named entity 'DESCRIBED' named entity 'HISTOPATHOLOGIST' named entity 'COLLECTED' named entity 'BIOPSIES' named entity 'STUDY' named entity 'BACKGROUND' named entity '857' named entity 'METHODS' named entity 'HOSPITAL' named entity 'histopathological' named entity 'biopsies' named entity 'collected' named entity 'Methods' named entity 'retrospective' named entity 'predominant' named entity 'This' named entity 'glomerulonephritis' named entity 'histological' named entity 'biopsies' named entity 'C3 glomerulonephritis' named entity 'C3 glomerulonephritis' named entity 'staining' named entity 'prognosis' named entity 'diagnostic accuracy' named entity 'glomerulopathy' named entity 'immunosuppression' named entity 'biopsy' named entity 'aetiology' named entity 'C3G' named entity 'complement-mediated' named entity 'C3G' named entity 'subendothelium' named entity 'Control group' named entity 'proteinuria' named entity 'Caucasians' named entity 'biopsy' named entity 'ANA' named entity 'disease recurrence' named entity 'renal biopsy' named entity 'immune complex' named entity 'SPSS' named entity 'Control group' named entity 'serological' named entity 'Bowman's capsule' named entity 'PIGN' named entity 'remission' named entity 'complement' named entity 'malignant hypertension' named entity 'immunoglobulin' named entity 'remission' named entity 'graft' named entity 'Caucasians' named entity 'morphology' named entity 'staining' named entity 'C3G' named entity 'relapse' named entity 'immunosuppression' named entity 'histological' named entity 'prognosis' named entity 'long term' named entity 'Control patients' named entity 'Haematuria' named entity 'France' named entity 'aetiology' named entity 'Control groups' named entity 'Control patients' named entity 'statistically significant' named entity 'remission' named entity 'remission' named entity 'Australian Capital territory' named entity 'complement' named entity 'survival rates' named entity 'renal disease' named entity 'type III'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software